Development of a dual monoclonal antibody immunoassay for total human kallikrein 2

Clinical Chemistry

Volumn 47, Issue 7, 2001, Pages 1218-1224

  Finlay, J A ^a   Day, J R ^a   Evans, C L ^a   Carlson, R ^a   Kuus Reichel, K ^a   Millar, L S ^a   Mikolajczyk, S D ^a   Goodmanson, M ^a   Klee, G G ^a   Rittenhouse, H G ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN INHIBITOR; KALLIKREIN; KALLIKREIN 2; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; KALLIKREIN KININ SYSTEM; MAJOR CLINICAL STUDY; MALE; PROSTATE DISEASE; PROSTATECTOMY;

EID: 0034949828     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.7.1218     Document Type: Article

References (43)

1. Prostate specific antigen role and function
2. Individual prostate-specific antigen (PSA) forms as prostate tumor markers
3. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate
4. Prostate specific antigen
5. The prostate-localized kallikreins: Prostate specific antigen (PSA) and human kallikrein 2 (hK2)
6. The new human kallikrein gene family - Implications in carcinogenesis
7. The human kallikrein gene family: A diversity of expression and function
8. Prostate-specific antigen and human glandular kallikrein: Two kallikreins of the human prostate
9. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker
10. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body
11. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions
12. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid
13. Identification of a novel complex of human kallikrein 2 (hK2) and protease inhibitor-6 (PI6)in prostate cancer tissues
14. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia
15. Detection of human glandular kallikrein, hK2 as its precursor form and in complex with protease inhibitors in prostate carcinoma serum
16. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma
17. Identification of human glandular kallikrein hK2 from LNCaP cells
18. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma
19. The use of human glandular kallikrein 2 (hK2) for the detection of prostate cancer: Preliminary analysis
20. Serum human glandular kallikrein-2 (hK2) protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen
21. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA
22. Expression of human glandular kallikrein, hK2, in mammalian cells
23. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors
24. Identity of prostate specific antigen and the semen protein P30 purified by a rapid chromatography technique
25. Seminal plasma protein p30: Simplified purification and evidence for identity with prostate specific antigen
26. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
27. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2
28. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1
29. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): Development of a dual antibody immunoassay for hK2 with negligible prostate specific antigen cross-reactivity
30. Development of antibodies for diagnostic assays
31. Evaluation of precision performance of clinical chemistry devices; NCCLS approved guideline EP5-A
32. A multiple comparison procedure for comparing several treatments with a control
33. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions
34. Contamination of purified PSA preparation by kallikrein hK2
35. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum
36. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum
37. A highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein
38. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen
39. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial
40. Clinical utility of measurements of free and total prostate-specific antigen (PSA): A review
41. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population
42. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer
43. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer